Methods and compositions for administering a specific wavelength phototherapy
Methods are disclosed for administering electromagnetic radiation (EMR), which may include filtering EMR from part of the EMR spectrum while allowing passage of EMR at a desired wavelength range. Uses may include the treatment of such conditions as psoriasis, vitiligo, pruritus, acne, vitamin-D deficiency and atopic dermatitis. Topical creams, sprays, or other compositions may be used, with or without dosimeters, or in conjunction with an application, which calculates local UV exposure and other factors relating to dosage.
1. A method of treating a human patient suffering from psoriasis, vitiligo, atopic dermatitis, and/or pruritis, comprising:
delivering, from ambient solar radiation, a dose of EMR to skin of a human subject by:
covering a region of the skin with a topical composition;
exposing the human subject to the ambient solar radiation for a predetermined period of time to generate an erythemally weighted irradiance therapeutic response; and
stopping the exposure of the human subject to the ambient solar radiation after the passage of the predetermined period of time;
wherein the topical composition comprises:
a cosmetic-grade carrier suitable for application to the human skin;
a first compound, suitable for application to human skin, which blocks more total radiation within wavelength range B (280 to 300 nm) than it blocks in wavelength range A (300 to 320 nm); and
a second compound, suitable for application to human skin, which blocks more total radiation within wavelength range C (320 to 340 nm) than it blocks in wavelength range A
wherein:
the topical composition blocks a percentage PF B of radiation in wavelength range B that is greater than a percentage PF A of radiation blocked in wavelength range A,
PF A is defined as:
P
F
A
=
1
-
∫
300
nm
320
nm
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
ⅆ
λ
∫
300
nm
320
nm
I
(
λ
)
·
w
(
λ
)
ⅆ
λ
PF B is defined as:
P
F
B
=
1
-
∫
280
nm
300
nm
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
ⅆ
λ
∫
280
nm
300
nm
I
(
λ
)
·
w
(
λ
)
ⅆ
λ
the topical composition blocks a percentage PF C of radiation in wavelength range C (320 to 340 nm) that is greater than PF A , wherein PF C is defined as:
P
F
C
=
1
-
∫
320
nm
340
nm
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
ⅆ
λ
∫
320
nm
340
nm
I
(
λ
)
·
w
(
λ
)
ⅆ
λ
PF C −PF A is at least about 5%; and
λ is a wavelength of radiation, I(λ) is an intensity of radiation according to solar irradiance standard ASTM G177-03 passing through the topical composition at a given wavelength in W/m 2 /nm, T(λ) is the mean transmittance of a topical composition determined using the methodology outline in the US FDA Broad Spectrum Test (21 CFR 201.327(j), Jul. 5, 2011), and w(λ) is a weighting function defined as:
w
(
λ
)
=
{
1
280
nm
<
λ
≤
298
nm
10
0.094
(
298
-
λ
)
298
nm
<
λ
≤
320
nm
PF B −PF A is at least about 10%; and
further wherein the first compound and the second compound are present in amounts and in a ratio such that the topical composition has an absorbance spectra forming a spectra valley defined by a wavelength range from 306 nm to 315 nm, the spectra valley allowing passage of light to generate the erythemally weighted irradiance therapeutic response,
wherein the topical composition comprises 4% hesperidin by weight percent and 1.125% or 2.5% diethylamino hydroxybenzoyl hexyl benzoate by weight percent.
2. The method of claim 1 , wherein PF B −PF A is at least about 25%.
3. The method of claim 2 , wherein PF B −PF A is at least about 50%.
4. The method of claim 1 , wherein PF C −PF A is at least about 10%.
5. The method of claim 4 , wherein PF C −PF A is at least about 15%.
6. The method of claim 1 , wherein the spectra valley allows for maximum transmittance of erythemally weighted EMR having a wavelength of 311 nm within a wavelength range from 280 to 320 nm.
7. A method of treating a human suffering from a skin disorder to produce a therapeutic response in the human patient by delivering, from ambient solar radiation, a dose of EMR within at least a predetermined wavelength band greater than about 300 nm to the skin of a human subject, comprising the steps of:
covering a region of the skin with a topical composition comprising:
a cosmetic-grade carrier suitable for application to the human skin;
a first compound, suitable for application to human skin, which blocks more total radiation within wavelength range B (280 to 300 nm) than it blocks in wavelength range A (300 to 320 nm); and
a second compound, suitable for application to human skin, which blocks more total radiation within wavelength range C (320 to 340 nm) than it blocks in wavelength range A
wherein the topical composition blocks a percentage PF B of radiation in wavelength range B that is greater than a percentage PF A of radiation blocked in wavelength range A,
PF A is defined as:
PF
A
=
1
-
∫
300
n
m
320
n
m
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
d
λ
∫
300
n
m
320
n
m
I
(
λ
)
·
w
(
λ
)
d
λ
PF B is defined as:
PF
B
=
1
-
∫
280
n
m
300
n
m
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
d
λ
∫
280
n
m
300
n
m
I
(
λ
)
·
w
(
λ
)
d
λ
the topical composition blocks a percentage PF C of radiation in wavelength range C (320 to 340 nm) that is greater than PF A , wherein PF C is defined as:
PF
C
=
1
-
∫
320
n
m
340
n
m
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
d
λ
∫
320
n
m
340
n
m
I
(
λ
)
·
w
(
λ
)
d
λ
PF C −PF A is at least about 5%; and
λ is a wavelength of radiation, I(λ) is an intensity of radiation according to solar irradiance standard ASTM G177-03 passing through the topical composition at a given wavelength in W/m 2 /nm, T(λ) is the mean transmittance of a topical composition determined using the methodology online in the US FDA Broad Spectrum Test (21 CFR 201.327(j), Jul. 5, 2011), and w(λ) is a weighting function defined as:
w
(
λ
)
=
{
1
280
nm
<
λ
≤
298
nm
10
0.094
(
298
-
λ
)
298
nm
<
λ
≤
320
nm
PF B −PF A is at least about 10%; and
wherein the first compound and the second compound are present in amounts and in a ratio such that the topical composition has an absorbance spectrum forming a spectrum valley defined by a wavelength range from 306 nm to 315 nm, the spectrum valley allowing passage of light to generate the erythemally weighted irradiance therapeutic response, wherein the topical composition comprises 4% hesperidin by weight percent and 1.125% or 2.5% diethylamino hydroxybenzoyl hexyl benzoate by weight percent;
exposing the person to the ambient solar radiation;
making a dosage calculation by executing a dosage calculator application program which has been stored in a general purpose digital computer's memory, to impart dosage calculation functionality to the general purpose digital computer by changing the state of the computer's arithmetic logic unit when a set of program instructions of the dosage calculator application program are executed, wherein the program instructions comprise the following steps:
obtaining (A) actual or predictive solar radiation data for a place in which the subject is located and a time during which the exposure is occurring or is to occur;
obtaining (B) a number or set of numbers representing the UV transmission characteristics of the topical composition within the predetermined wavelength band; and
calculating, based on a set of available data which includes (A) and (B), a predetermined period of time reflecting a therapeutically effective amount of exposure time to the ambient solar radiation for treatment of a condition of the human subject in need of therapeutic treatment by exposure to UV light; and
stopping the exposure of the person to the ambient solar radiation after the passage of the predetermined period of time.
8. The method of claim 7 , wherein the skin disorder is selected from the group consisting of psoriasis, vitiligo, acne, atopic dermatitis, and pruritis.
9. A method of treating a human patient suffering from psoriasis, vitiligo, atopic dermatitis, and/or pruritis, comprising:
delivering, from ambient solar radiation, a dose of EMR to skin of a human subject by:
covering a region of the skin with a topical composition;
exposing the human subject to the ambient solar radiation for a predetermined period of time to generate an erythemally weighted irradiance therapeutic response; and
stopping the exposure of the human subject to the ambient solar radiation after the passage of the predetermined period of time;
wherein the topical composition comprises:
a cosmetic-grade carrier suitable for application to the human skin;
a first compound, suitable for application to human skin, which blocks more total radiation within wavelength range B (280 to 300 nm) than it blocks in wavelength range A (300 to 320 nm); and
a second compound, suitable for application to human skin, which blocks more total radiation within wavelength range C (320 to 340 nm) than it blocks in wavelength range A
wherein:
the topical composition blocks a percentage PF B of radiation in wavelength range B that is greater than a percentage PF A of radiation blocked in wavelength range A,
PF A is defined as:
PF
A
=
1
-
∫
300
n
m
320
n
m
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
d
λ
∫
300
n
m
320
n
m
I
(
λ
)
·
w
(
λ
)
d
λ
PF B is defined as:
PF
B
=
1
-
∫
280
n
m
300
n
m
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
d
λ
∫
280
n
m
300
n
m
I
(
λ
)
·
w
(
λ
)
d
λ
the topical composition blocks a percentage PF C of radiation in wavelength range C (320 to 340 nm) that is greater than PF A , wherein PF C is defined as:
PF
C
=
1
-
∫
320
n
m
340
n
m
I
(
λ
)
·
w
(
λ
)
·
T
(
λ
)
d
λ
∫
320
n
m
340
n
m
I
(
λ
)
·
w
(
λ
)
d
λ
PF C −PF A is at least about 5%; and
λ is a wavelength of radiation, I(λ) is an intensity of radiation according to solar irradiance standard ASTM G177-03 passing through the topical composition at a given wavelength in W/m 2 /nm, T(λ) is the mean transmittance of a topical composition determined using the methodology outline in the US FDA Broad Spectrum Test (21 CFR 201.327(j), Jul. 5, 2011), and w(λ) is a weighting function defined as:
w
(
λ
)
=
{
1
280
nm
<
λ
≤
298
nm
10
0.094
(
298
-
λ
)
298
nm
<
λ
≤
320
nm
PF B −PF A is at least about 10%; and
further wherein the first compound and the second compound are present in amounts and in a ratio such that the topical composition has an absorbance spectra forming a spectra valley defined by a wavelength range from 306 nm to 315 nm, the spectra valley allowing passage of light to generate the erythemally weighted irradiance therapeutic response,
further wherein the first compound consists of silymarin and the second compound consists of diethylamino hydroxybenzoyl hexyl benzoate in a weight to weight ratio within a range from 1:2 to 5:6.
10. The method of claim 9 , wherein PF B −PF A is at least about 25%.
11. The method of claim 10 , wherein PF B −PF A is at least about 50%.
12. The method of claim 9 , wherein PF C −PF A is at least about 10%.
13. The method of claim 12 , wherein PF C −PF A is at least about 15%.
14. The method of claim 9 , wherein the spectra valley allows for maximum transmittance of erythemally weighted EMR having a wavelength of 311 nm within a wavelength range from 280 to 320 nm.